SPONSOR
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 3
Conditions studied: Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)LymphomaRelapsed or Refractory Multiple Myeloma (RRMM)
NCT06788639
Recruiting
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Chronic Lymphocytic Leukemia (CLL)
NCT07015242 Phase 2
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
NCT06615479 Phase 3
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)